Danaher Corporation (NYSE: DHR) Q2 2025 Earnings | 07/22/2025

About this video

Danaher Corporation reported its second quarter 2025 financial results, highlighting continued resilience and solid growth despite a complex macroeconomic environment. Revenues for the quarter rose 3.5% year-over-year to $5.9 billion, with non-GAAP core revenue growing 1.5%. The company’s adjusted diluted net earnings per share reached $1.80, a 4.7% increase from Q2 2024, exceeding consensus expectations and reflecting strong execution and robust bioprocessing momentum. On a GAAP basis, net earnings were $555 million, or $0.77 per diluted share. Danaher’s Bioprocessing segment drove results with 8% year-over-year revenue growth, made possible by double-digit consumables growth and strong order trends from large pharmaceutical contract manufacturers. This offset modest declines in the Life Sciences segment, where revenues were stable but margins tightened. Diagnostics reported steady revenue gains of 2% year-over-year, with strength in clinical diagnostics helping balance regional and segment headwinds. Gross profit margin was 59.3%, and the company maintained an adjusted operating profit margin of 27.3%. Free cash flow for Q2 was $1.1 billion, supporting ongoing investment, while operating cash flow was $1.3 billion for the quarter. Geographically, developed markets saw low single-digit core revenue growth, led by gains in North America and Western Europe. High-growth markets were flat overall, as a solid performance across regions was offset by a mid-single-digit revenue decline in China, largely due to changes in reimbursement and procurement within diagnostics. Disciplined cost controls and a focus on consumables, recurring revenue, and portfolio resilience allowed Danaher to raise its full-year 2025 adjusted diluted net EPS guidance to $7.70–$7.80, up from the previous $7.60–$7.75 range. Management emphasized ongoing structural cost initiatives targeting $150 million in annualized savings, while reaffirming long-term high single-digit percentage growth targets for bioprocessing. Tariff exposure was further reduced to several hundred million dollars through supply chain adjustments. President and CEO Rainer M. Blair attributed the quarter’s success to the Danaher Business System, emphasizing balanced growth, strategic cost management, and the company’s positioning in non-discretionary healthcare markets, with more than 80% of sales from recurring consumables and services. Looking ahead, Danaher remains focused on leveraging its strong balance sheet, fostering innovation, and capitalizing on long-term secular trends in biopharmaceuticals and healthcare technology. About Inside Ticker: For up-to-date earnings analysis, market insights, and in-depth updates on Danaher Corporation (NYSE: DHR) and other global leaders in life sciences and diagnostics, follow Inside Ticker and visit InsideTicker.com for expert coverage and real-time financial news. #Danaher #DHR #Q22025 #Earnings #FinancialResults #Bioprocessing #LifeSciences #Diagnostics #RecurringRevenue #EPS #FreeCashFlow #OperationalExcellence #CostManagement #Guidance #Healthcare #Pharmaceuticals #China #GrowthStrategy #InsideTicker